Work

Avenger 500, a phase III open-label randomized trial of the combination of CPI-613 with modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas.

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.4_suppl.tps479

Authors: Philip Agop Philip, Marc E. Buyse, Angela Tatiana Alistar, Caio Max Sao Pedro Rocha Lima, Sanjeev Luther, Timothy S. Pardee, Eric Van Cutsem

Institutions: Wayne State University, The Barbara Ann Karmanos Cancer Institute, Atrium Health Wake Forest Baptist, Wake Forest Baptist Comprehensive Cancer Center, University of Miami, KU Leuven

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2913145248

Cites:

Cited by: 16

Related to: 10